The current status of percutaneous mitral valve repair  by Schofield, R.S. & Schofield, P.M.
Journal of the Saudi Heart Association (2010) 22, 111–114King Saud University
Journal of the Saudi Heart Association
www.ksu.edu.sa
www.sha.org.sa
www.sciencedirect.comEDITORIALThe current status of percutaneous mitral valve repairValvular heart disease is a common clinical problem and mitral
valve regurgitation is the lesion seen most frequently. The
mitral valve is a complex structure and regurgitation of the
valve may occur due to abnormalities of the valve leaﬂets,
the chordae tendineae, the papillary muscles or the mitral valve
annulus. The aetiology of mitral regurgitation may be classi-
ﬁed as either organic or functional. Organic regurgitation is
due to structural changes in the valve or subvalvar apparatus,
such as degenerative (including mitral valve prolapse) and
rheumatic disease, infective endocarditis and annular calciﬁca-
tion. Functional regurgitation occurs in the setting of a struc-
turally normal valve when changes in left ventricular geometry
lead to failure of coaptation of the valve leaﬂets. This may be
secondary to underlying coronary artery disease or a dilated
cardiomyopathy.
Organic mitral regurgitation occurs when degenerative con-
ditions lead to structural changes in the leaﬂets or the subval-
var apparatus. Mitral valve prolapse occurs when part (or all)
of one (or both) of the valve leaﬂets displace retrogradely into
the left atrium during systole. In developed countries, this is
the most common cause of chronic mitral regurgitation. Sev-
eral causative genetic chromosomal abnormalities have been
identiﬁed although the disease may also be acquired. A defect
in collagen results in the valve leaﬂets and chordae tendineae
becoming baggy and fragile. As a result, when the valve closes,
the leaﬂets are not pulled taught and prolapse into the left at-
rium. The chordae are prone to rupture and over time there is
annular dilatation. Although many patients remain asymp-
tomatic and have a normal life expectancy, between 5% and
10% of patients may progress to severe mitral regurgitation
(Barlow and Pocock, 1979). Patients who develop symptoms
or have signs of signiﬁcant mitral regurgitation with left ven-
tricular dilatation and/or dysfunction should be considered
for surgery.
The current surgical options are mitral valve replacement
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Production and hosting by Elsevierpatient’s native valve. Although there are no randomised trials
comparing mitral valve replacement and repair, a meta-analy-
sis of the observational studies favoured mitral repair in sur-
vival outcomes (Shuhaiber and Anderson, 2007). The most
common lesion identiﬁed is prolapse of the middle scallop of
the posterior leaﬂet. Repairs of the anterior leaﬂet or both leaf-
lets are more complicated. The goals of surgical repair are to
ensure an adequate surface of coaptation of both leaﬂets in
systole, restore full leaﬂet motion and prevent progressive
annular dilatation by inserting an annuloplasty ring. The oper-
ative mortality is typically up to 3% (Gillinov et al., 1998) and
recurrence of the mitral regurgitation may occur in up to 30%
of patients (Filsouﬁ and Carpentier, 2007).
Mitral regurgitation may result from rheumatic heart
disease, although mitral stenosis or mixed mitral valve disease
occur more commonly. Ischaemic mitral regurgitation results
from the sequelae of underlying coronary artery disease. Acute
myocardial ischaemia may result in transient dysfunction of
the subvalvar apparatus and myocardial infarction may cause
permanent dysfunction of the subvalvar apparatus. Generally
the outcome of patients with ischaemic mitral regurgitation
is worse than those patients with similarly severe regurgitation
from another cause, due to the superimposed left ventricular
dysfunction. In patients with acute papillary muscle rupture,
urgent mitral valve surgery with revascularisation should be
considered. The case for surgery with chronic ischaemic mitral
regurgitation is less clear cut. Mitral valve replacement and/or
mitral valve annuloplasty with concomitant coronary artery
grafting needs to be considered.
With functional mitral regurgitation, there is incomplete
mitral valve closure in the setting of a structurally normal
valve. This may occur due to global left ventricular dysfunc-
tion reducing the ventricular force acting to close the leaﬂets,
dilatation of the mitral annulus and alterations in left ventric-
ular geometry at the site from which the papillary muscles
arise. Although all three factors may contribute to the mitral
regurgitation it appears that the predominant mechanism is
apical displacement of the papillary muscles with tenting of
the leaﬂets away from the annulus and subsequent incomplete
leaﬂet coaptation (Levine and Schwammenthal, 2005).
Functional mitral regurgitation is found frequently in
patients with impaired left ventricular systolic function and
is associated with a worse prognosis in this group of patients.
Furthermore, there is an incremental risk of mortality with
112 Editorialincreasing grades of mitral regurgitation. In a 10 year cohort
study, the prevalence and prognostic implication of mitral
regurgitation was evaluated in patients undergoing echocardi-
ography within 30 days of myocardial infarction. Mitral regur-
gitation was found in 50% of patients. After around 5 years of
follow up, mitral regurgitation was associated with a greater
than threefold risk of heart failure and the presence of moder-
ate/severe regurgitation was independently associated with a
55% increased risk of death (Bursi et al., 2005).
Medical therapy may reduce regurgitant volumes in
patients with functional mitral regurgitation, but the primary
effect is for treatment of the antecedent heart failure. Beta-
blockers and ACE inhibitors usually help to restore the normal
orientation of the papillary muscles to the annulus. Vasodila-
tors, including nitrates and hydralazine, in association with
diuretics may reduce the severity of mitral regurgitation. A
subset of patients with an increased QRS duration may be suit-
able for cardiac resynchronisation therapy (Auricchio and
Abraham, 2004). The standard surgical treatment for func-
tional mitral regurgitation involves annuloplasty with a ring
that is designed to correct annular dilatation, restore leaﬂet
coaptation and reduce the effective regurgitant oriﬁce area.
Chronic volume overload contributes to progressive ventricu-
lar remodelling, which in term begets progressive mitral regur-
gitation. Surgical correction may break this cycle, although the
operative risk in this patient population is not insigniﬁcant.
When the various observational studies are examined, it be-
comes apparent that the operative risk is between 3% and
6% (Wu et al., 2005; Mihaljevic et al., 2007). In most patients
there is an improvement in NYHA functional class, exercise
capacity and quality of life (Mihaljevic et al., 2007; Acker
et al., 2006). Some, but not all, studies have demonstrated
positive functional outcomes, such as reverse remodelling
and reductions in end-diastolic and end-systolic volumes
(Acker et al., 2006; Bolling et al., 1998). There are therefore
reservations regarding surgery for functional mitral regurgita-
tion in view of the high surgical mortality, the fact that the
primary problem is with advanced left ventricular dysfunction
and the high rate of recurrence of valvular regurgitation fol-
lowing surgery. It is clear that careful patient selection is vital
since currently there are no randomised controlled trials com-
paring surgery with medical or device therapy.
Percutaneous treatment of the mitral valve has been in
development since balloon valvuloplasty for mitral stenosis
was performed over 25 years ago (Inoue et al., 1984). The ther-
apies for mitral regurgitation have been more difﬁcult to reﬁne.
Currently we have various options available which follow sim-
ilar approaches to the established surgical procedures. These
include leaﬂet repair, coronary sinus annuloplasty, direct
annuloplasty as well as chamber remodelling devices.
Although mitral valve replacement and valve repair are well
established and effective methods of treating mitral regurgita-
tion, some patients may not be suitable for surgery. The pres-
ence of major co-morbidity or severe left ventricular
dysfunction may be associated with a high surgical risk. The
percutaneous technologies negate the use of sternotomy and
cardiopulmonary bypass and may offer an alternative ap-
proach in high risk patients.
It is possible to create a double oriﬁce within the mitral
valve by suturing the free edges of the anterior and posterior
leaﬂets together using a percutaneous approach. This tech-
nique was ﬁrst described by Alﬁeri in 1990. It may be usefulin patients with mitral regurgitation resulting from central
malcoaptation of the valve. When this technique is used dur-
ing open heart surgery it is common practice to deploy an
annuloplasty ring simultaneous. This is not performed in
the percutaneous procedure and the added beneﬁt of an
annuloplasty ring remains uncertain. The Mobius device uses
a transeptal suction catheter to secure the mitral valve leaﬂets
and subsequently deploy percutaneous sutures. Feasibility tri-
als in animals and humans proved unsatisfactory and cur-
rently this technique is not being used in clinical practice.
The Mitraclip device uses a transeptal catheter with a metallic
clip to grasp the two free edges of the anterior and posterior
leaﬂets and join them. Transoesophageal echocardiography
guides the deployment and is used to assess the valve
throughout the procedure. Clips can be removed if not satis-
factory without injury to the leaﬂets or subvalvar structure.
The operator can optimise the reduction in mitral regurgita-
tion by trialing several points along the line of coaptation.
The transoesophageal echocardiogram enables functional
assessment of the valve and the degree of regurgitation dur-
ing the procedure. If the operator is unable to deploy the
Mitraclip device with a satisfactory result, the device can be
removed entirely and other options considered. The design
of the device does not preclude subsequent surgical interven-
tion even if left in situ. It is possible to deploy an additional
Mitraclip if necessary.
The phase I feasibility trial of Mitraclip, EVEREST I, in-
cluded patients with functional or degenerative mitral regurgi-
tation of grade 3 or above. Patients with rheumatic mitral
regurgitation and severe left ventricular dysfunction were ex-
cluded. The Mitraclip was implanted in 42 patients and in
74% the degree of mitral regurgitation was reduced to grade
2 or below at the time of discharge. This improvement was
maintained on echocardiographic follow up at 6 months (Herr-
mann and Feldman, 2006). The ﬁrst randomised trial compar-
ing Mitraclip with conventional surgery in patients with at
least grade 3 regurgitation, EVEREST II, excluded patients
with left ventricular dysfunction and/or annular dilatation.
The early results have demonstrated a reduction in mitral
regurgitation to grade 1 or less in 64% of patients. This was
associated with clinical improvement and a reduction in
NYHA class. At 3 years there was freedom from death of
90% and freedom from surgery of 76% in those undergoing
percutaneous repair (Feldman et al., 2009). The percutaneous
procedure has been associated with a low morbidity and mor-
tality. Partial clip detachment occurred in 9% of cases – i.e.
detachment from one of the two valve leaﬂets. The vast major-
ity of patients reported had mitral valve prolapse. It remains to
be seen whether this technique will have the same success in
patients with functional mitral regurgitation.
The EVEREST II high risk registry recruited 78 symptom-
atic patients with mitral regurgitation of grade 3 or more who
were considered to be at high risk from conventional surgery
(Kar, 2009). Their surgical mortality was considered to be
greater than 12% and most had several co-morbidities. Forty
six patients had functional mitral regurgitation and 32 had or-
ganic regurgitation. The acute procedural success was 96%.
The mean predicted 30 day mortality was 17.8%, with an ac-
tual mortality of 7.7%. At 12 months, 74% of patients were
NYHA functional class I or II as compared with 9% prior
to the procedure. There was an associated improvement in left
ventricular volumes and function.
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tral valve annulus indirectly via the coronary sinus, including
the MONARC device, the CARILLON device and the PTMA
device. The MONARC device consists of two self expanding
nitinol anchors connected by a bridge which gradually short-
ens following implantation. This has the effect of anterior dis-
placement of the posterior mitral annulus with reductions in
mitral annulus diameter and septal lateral distance. The EVO-
LUTION I trial evaluated the safety and efﬁcacy of the device
in 72 patients with functional mitral regurgitation due to either
dilated or ischaemic cardiomyopathy (Harnek, 2009). Success-
ful implantation occurred in 82% of patients. At 2 year follow
up, 55% of patients had at least one grade reduction in the de-
gree of mitral regurgitation. There were more responders if the
degree of regurgitation was greater at baseline. Of these with
grade 3 or more regurgitation at baseline, 80% had an
improvement of at least 1 grade at follow up. The early data
indicates feasibility, safety and durability of the MONARC de-
vice, with larger trials ongoing (EVOLUTION II).
The CARRILON device consists of distal and proximal
nitinol based anchors that are separated by a metal bridge.
After the distal anchor is deployed in the great cardiac vein,
manual tension is applied to the system which results in plica-
tion of the mitral annulus. As there is an immediate shortening
of the coronary sinus, deployment of the device can be guided
by echocardiographic measures of the reduction in mitral
regurgitation. Unlike the MONARC system, the CARILLON
device is fully retrievable up to ﬁnal release. This may be help-
ful if there is concern regarding coronary artery compression,
displacement of the distal anchor or insufﬁcient reduction in
mitral regurgitation.
The AMADEUS trial evaluated the feasibility and safety of
the CARILLON device in 48 patients with either dilated or
ischaemic cardiomyopathy and moderate/severe mitral regur-
gitation. A total of 18 patients did not have the device im-
planted due to problems with access, coronary artery
compromise or inadequate reduction in mitral regurgitation.
At 6 month follow up there was a reduction in the degree of
mitral regurgitation and an improvement in symptoms. At
baseline 80% of patients were in NYHA class III or IV
whereas at 6 months 88% were in NYHA class I or II (Schofer
et al., 2009). A second study, the TITAN trial, is ongoing and
will evaluate the longer term safety and efﬁcacy (up to 5 years).
The PTMA device consists of a polytetraﬂuoroethylene
(PTFE) catheter that is delivered into the coronary sinus via
the subclavian vein, with the distal tip seated in the anterior
interventricular vein, and the proximal hub left in a subclavian
pocket to enable further access at a later date. The catheter con-
tains three separate lumens through which nitinol rods of vary-
ing stiffness, length and taper can be inserted. The device
produces an outward force at its proximal and distal segments
such that the mid-portion of the posterior mitral annulus is
displaced anteriorly with subsequent reduction of the septal–
lateral dimension and mitral regurgitant oriﬁce. Since the num-
ber, stiffness and length of the rods can be varied with time,
modiﬁcation of the geometry of the mitral annulus can be
achieved. The PTOLEMY I trial evaluated the feasibility and
safety of the PTMA device in 27 symptomatic patients with
moderate-severe functional mitral regurgitation. The device
was successfully implanted in only 9 patients. In these patients,
there was a reduction in the degree of mitral regurgitation and areduction in the mitral annulus septal–lateral dimension (Sack
et al., 2009).
Direct mitral valve annuloplasty has been performed using
the Mitralign system. A guiding catheter is delivered to the left
ventricle using a retrograde transaortic approach and posi-
tioned beneath the posterior mitral leaﬂet. Radio frequency
is used to penetrate a number of wires through the posterior
annulus which are then anchored. The anchors are connected
by a drawstring suture which can reduce the annular dimen-
sions when tethered (Alqooﬁ and Feldman, 2009). At the pres-
ent time, little clinical data is available.
In conclusion, it is now possible to treat both organic and
functional mitral regurgitation using a percutaneous approach.
These devices are predominantly designed to either enable di-
rect repair of the mitral leaﬂets or to achieve mitral annulo-
plasty via a coronary sinus approach. The early studies of
feasibility, safety and clinical response have been encouraging.
It is likely that these devices will be used increasingly in future
years and further developments/modiﬁcations will continue to
be made. As further clinical trials are conducted it will become
clearer as to which patients will beneﬁt from which device and
also at what stage the devices should be used during the natu-
ral history of the patients mitral valve regurgitation.References
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